查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856609

眼科给药系统市场：按药物类型、给药装置类型、产品类型、製剂类型、给药方式、应用和最终用户划分－全球预测，2025-2032年

Ophthalmic Drug Delivery System Market by Drug Type, Delivery Device Type, Product Type, Formulation Type, Mode Of Delivery, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，眼科药物输送系统市场规模将达到 310.6 亿美元，复合年增长率为 9.07%。

关键市场统计数据
基准年 2024 155亿美元
预计年份：2025年 168.4亿美元
预测年份 2032 310.6亿美元
复合年增长率 (%) 9.07%

明确的策略方向，整合临床、监管和商业方面的考虑，正在改变创新眼部药物传输技术的开发和应用。

在技​​术、监管和临床因素的共同推动下，眼科药物递送领域正经历着深刻的变革时期。生物材料、微型化递送装置和控制释放药物技术的进步，使得治疗眼前节和后节眼部疾病变得更安全有效。同时，随着外科医生、眼科医生和医疗保健专业人员采用治疗方法，视网膜疾病、青光眼和干眼症的临床路径也在不断发展。这种转变为製药公司、医疗器材製造商和委外研发机构在整个研发生命週期中进行更深入的合作创造了机会。

技术融合、基于价值的证据要求以及数位医疗的整合，正在推动眼科药物输送创新领域的新范式。

眼部给药领域的竞争优势正因多项变革性进展而重新定义，而科技的融合正引领着这项变革。微针、缓释性植入和药物释放型隐形眼镜等新兴平台正在提高局部生物有效性，同时降低给药频率，并正从概念验证迈向临床检验。同时，製剂科学，特别是半固态製剂和奈米颗粒基质的进步，正在延长药物在眼内的停留时间并提高药物稳定性，从而拓宽小分子药物和生物製药的治疗窗口。这些技术进步正在为慢性视网膜疾病和术后復健释放新的治疗途径。

2025年关税政策主导的供应链重组促使企业采取策略性近岸外包、供应商多元化等措施，并更重视原物料均价和生产韧性。

2025年美国关税政策带来了一系列供应链动态变化，产业相关人员在製定采购、生产和分销策略时必须考虑这些变化。关税调整影响了眼科给药系统中使用的许多上游组件和原材料的成本结构，包括聚合物基材、无菌包装材料和专用设备。为此，许多公司已开始重新评估其供应商组合，并加快近岸或国内生产能力建设，以维持供应的连续性并减轻进口关税的影响。

结合治疗方法、递送机制、製剂科学、临床应用和终端用户动态的精细化细分方法，能够揭示清晰的开发和商业化路径。

细緻的细分框架揭示了不同治疗标靶、给药机制、产品分类、製剂类型、给药途径、临床应用和终端用户环境等方面的差异化创新路径和应用模式。考虑到药物类型，例如抗VEGF疗法、抗青光眼药物、抗发炎药物、感染疾病物和抗过敏药物，每种药物都具有独特的药物动力学和安全性特征，这些特征会影响给药方式和製剂策略的选择。给药装置类型多种多样，从隐形眼镜介导系统和眼内植入到微针、眼内植入物、眼用喷雾剂和局部凝胶，每种装置在药物停留时间、患者舒适度和生产复杂性方面都各有优劣。

区域监管差异、报销动态以及区域生产能力决定了世界各地不同的市场进入和商业化策略。

区域动态持续影响美洲、欧洲、中东和非洲以及亚太地区的临床应用、监管策略和商业化重点，每个地区都面临独特的推动因素和挑战。在美洲，完善的临床试验网路和先进的医保报销系统为缓释性缓释和植入式药物产品的推广应用创造了有利环境。

我们在设备设计、配方科学、监管专业知识和生产扩充性的综合能力正在重塑眼科领域的竞争优势。

在眼科药物递送领域，竞争优势日益取决于企业在器材设计、製剂研发、临床开发和法规事务等方面的综合能力。拥有深厚控制释放技术专长、成熟的无菌生产能力以及清晰的监管路径的企业，在将差异化治疗方法推向市场方面保持着优势。製药企业与器材研发合作伙伴之间的策略联盟也日益普遍，这种合作开发模式能够将技术创新与临床终点和支付方的证据要求结合。

透过采取整合策略，同时促进联盟和智慧财产权保护，加速推广应用并降低商业化风险。

业界领导者应采取一系列切实可行的倡议，旨在加速眼科药物递送领域的研发、促进应用并巩固其商业性地位。首先，在产品设计初期就应纳入监管和卫生经济规划，以建立符合支付方预期并有助于报销谈判的证据基础。其次，应优先考虑模组化供应链策略，将近岸生产与有效的多元化采购相结合，以降低关税波动和原材料短缺的风险。第三，应投资于组合药物研发，透过建立联盟将独特的分子与差异化的递送平台结合，从而提高市场准入门槛，并为临床医生和患者创造更具吸引力的价值提案。

本文采用透明的三管齐下的调查方法，结合专家访谈、文献综合和情境分析，为提出的见解和建议奠定了基础。

本分析的调查方法结合了多源资讯、专家访谈和文献综述，旨在全面展现眼科药物递送领域的现况。主要定性资讯是透过对临床研究人员、法规顾问、采购负责人和产品开发主管的结构化访谈获得的，以深入了解临床工作流程、器械操作和支付方证据需求等方面的实际应用。二级资讯来源包括同行评审文献、法规指导文件和技术白皮书，以支持对递送技术和製剂性能的机制性理解。

技术、证据产生和供应链韧性的策略结合将决定哪些组织能够将眼科护理服务的创新转化为持久的临床和商业性成功。

总之，眼科药物递送领域正处于曲折点，技术进步、监管预期和供应链现实交织在一起，重新定义了治疗方法的研发和商业化方式。缓释性平台、创新器材模式和改进的製剂策略正在融合，以减轻治疗负担并拓展复杂眼科疾病的治疗选择。同时，经济和政策压力正促使各机构采取更具韧性的筹资策略，并提供支付方和医疗服务提供者所需的临床和经济证据，以支持疗法的推广应用。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 可生物降解的眼内植入兴起，为湿性老年黄斑部病变（AMD）患者提供持续药物缓释性。
  • 将微针为基础的眼贴整合到治疗慢性眼科疾病的微创疗法中
  • 采用新型奈米载体製剂提高角膜渗透性和生物有效性
  • 拓展基于病毒载体的基因治疗方法以治疗遗传性视网膜疾病
  • 患者友善原位凝胶眼药水的出现，使得药物能够在眼表长期保留。
  • 使用含有药物储存器的隐形眼镜来控制释放
  • 生技公司与眼科器材製造商伙伴关係，共同开发药械组合产品
  • 应用人工智慧预测模型优化眼科药物给药的个人化剂量
  • 针对个别患者解剖结构量身定制的3D列印眼部植入的出现，为标靶药物输送提供了可能。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类型分類的眼科药物传输系统市场

  • 抗过敏
  • 抗青光眼
  • 抗感染药物
  • 抗发炎药
  • 抗 VEGF

9. 依给药装置类型分類的眼科药物传输系统市场

  • 隐形眼镜药物输送
  • 眼内植入
  • 微型针
  • 眼科植入物
  • 眼用喷雾剂
  • 局部凝胶

第十章 眼科药物输送系统市场（依产品类型划分）

  • 非处方药製剂
  • 处方药产品
    • 控制释放製剂
    • 标准製备

第十一章 眼科药物传递系统市场（依剂型类型划分）

  • 液体配方
  • 半固态製剂
    • 奶油
    • 凝胶
    • 软膏
  • 固态剂型
    • 胶囊
    • 药片

12. 依给药方式分類的眼科药物输送系统市场

  • 眼
  • 玻璃体内注射
  • 眼周
  • 全身
  • 局部的

第十三章 眼科药物传递系统市场（依应用领域划分）

  • 过敏治疗
  • 干眼症
  • 青光眼
  • 眼部感染疾病
  • 视网膜疾病
  • 手术恢復

第十四章 眼科药物传输系统市场（依最终用户划分）

  • 医院
  • 眼科诊所
  • 研究所

15. 眼科药物输送系统市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 眼科药物传输系统市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 各国眼科药物输送系统市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Alcon Vision LLC
    • Apotex Inc.
    • AptarGroup, Inc.
    • Bausch Health Companies Inc.
    • Bayer AG
    • Carl Zeiss AG
    • DifGen Pharmaceuticals LLC
    • EyePoint Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche AG
    • Genentech, Inc.
    • Gerresheimer AG
    • Iskon Remedies
    • Johnson & Johnson Service, Inc.
    • Mati Therapeutics, Inc.
    • Merck KGaA
    • MgShell SRL
    • Nicox SA
    • Novartis AG
    • Ocular Therapeutix Inc.
    • Oculis SA
    • Pfizer Inc.
    • Recipharm AB
    • Regeneron Pharmaceuticals, Inc.
    • Santen Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries, Inc.
    • Terumo Corporation
    • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-742BD51829D7

The Ophthalmic Drug Delivery System Market is projected to grow by USD 31.06 billion at a CAGR of 9.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 15.50 billion
Estimated Year [2025] USD 16.84 billion
Forecast Year [2032] USD 31.06 billion
CAGR (%) 9.07%

A clear and strategic orientation toward integrated clinical, regulatory, and commercial considerations is reshaping how ophthalmic drug delivery innovations are developed and adopted

The ophthalmic drug delivery landscape is undergoing a period of substantive transformation driven by converging technological, regulatory, and clinical forces. Advances in biomaterials, miniaturized delivery devices, and controlled-release pharmacology are enabling safer, more effective therapies for anterior and posterior segment diseases. At the same time, clinical pathways for retinal disorders, glaucoma, and dry eye are evolving as surgeons, ophthalmologists, and allied health professionals adopt new modalities that reduce treatment burden and improve adherence. These shifts are creating opportunities for pharmaceutical firms, device manufacturers, and contract development organizations to collaborate more deeply across the development lifecycle.

Regulatory agencies globally are emphasizing real-world evidence and quality-by-design principles, which is reshaping development timelines and necessitating earlier consideration of manufacturability and post-market surveillance plans. Consequently, stakeholders must balance innovation with pragmatic commercialization strategies. As a result, product teams are increasingly integrating regulatory, clinical, and commercial inputs from project inception, ensuring that candidate formulations and devices are designed to meet both patient needs and payer expectations.

Technological convergence, value-based evidence demands, and digital care integration are jointly accelerating new paradigms in ophthalmic drug delivery innovation

Several transformative shifts are redefining competitive advantage in ophthalmic drug delivery, with technology convergence standing at the forefront. Emerging platforms such as microneedles, sustained-release implants, and drug-eluting contact lenses are moving from proof of concept toward clinical validation, reducing dosing frequency while enhancing localized bioavailability. Parallel advances in formulation science-particularly in semi-solid and nanoparticle-enabled matrices-are improving ocular residence time and drug stability, thereby expanding the therapeutic window for both small molecules and biologics. These technological advances are unlocking new therapeutic approaches for chronic retinal diseases and postoperative recovery.

In addition, payer and health-system requirements for demonstrated value are prompting manufacturers to generate meaningful patient-reported outcomes and health economics evidence earlier in development. This has led to strategic partnerships between device makers and pharmaceutical developers to combine delivery technology with differentiated molecules, thereby creating product ecosystems rather than stand-alone therapies. Finally, the digitization of care pathways, including remote monitoring and teleophthalmology, is influencing device design and patient engagement strategies, creating opportunities for integrated offerings that connect therapeutic performance with longitudinal patient data.

Tariff-driven supply chain recalibration in 2025 prompted strategic near-shoring, supplier diversification, and heightened focus on material equivalency and production resilience

United States tariff policy in 2025 introduced a set of supply-chain dynamics that industry stakeholders must account for when planning sourcing, manufacturing, and distribution strategies. Tariff adjustments affected the cost structure of many upstream components and raw materials used in ophthalmic delivery systems, including polymer substrates, sterile packaging materials, and specialized devices. In response, many firms began reassessing supplier portfolios and accelerating near-shore or domestic production capabilities to maintain supply continuity and mitigate exposure to import tariffs.

Consequently, procurement teams increased emphasis on supplier diversification and multi-sourcing strategies, while manufacturing leaders prioritized process robustness to limit dependence on single vendors. Regulatory and quality teams collaborated with operations to validate alternative suppliers and ensure material equivalency. As an outcome, some organizations shifted toward vertically integrated models or strategic partnerships with regional contract manufacturers to preserve lead times and control costs. These adaptations improved resilience but also required capital allocation decisions to balance flexibility against operational efficiency.

A granular segmentation approach connecting therapeutics, delivery mechanisms, formulation science, clinical applications, and end-user dynamics reveals distinct development and commercialization pathways

A nuanced segmentation framework reveals differentiated innovation pathways and adoption profiles across therapeutic targets, delivery mechanisms, product classifications, formulation types, administration routes, clinical applications, and end-user settings. When considering drug type, anti-VEGF therapies, anti-glaucoma agents, anti-inflammatory compounds, anti-infective molecules, and anti-allergy medications each present unique pharmacokinetic and safety profiles that influence selection of delivery modalities and formulation strategies. Delivery device typologies range from contact lens-mediated systems and intraocular implants to microneedles, ocular inserts, ophthalmic sprays, and topical gels, with each device class offering distinct trade-offs in terms of residence time, patient comfort, and manufacturing complexity.

Product type distinctions between over-the-counter formulations and prescription-only products drive divergent regulatory pathways and commercialization models, with prescription products often requiring more complex controlled-release approaches. Formulation types-liquid, semi-solid, and solid-further determine stability requirements and dosing precision; semi-solid forms such as creams, gels, and ointments must balance ocular tolerability with retention, while solid forms including capsules and tablets are generally aligned with systemic or periocular delivery strategies. Modes of delivery such as intraocular, intravitreal, periocular, systemic, and topical routes impose different clinical workflows and safety monitoring protocols. Application areas span allergy treatment, dry eye syndrome, glaucoma, ocular infections, retinal disorders, and surgical recovery, each shaping clinical endpoints and adoption levers. Finally, end users including hospitals, ophthalmic clinics, and research organizations influence procurement cycles, reimbursement considerations, and requirements for training and post-market support, highlighting where commercialization efforts should be concentrated for maximum clinical uptake.

Regional regulatory diversity, reimbursement dynamics, and localized manufacturing capacity define differentiated market-entry and commercialization strategies across global regions

Regional dynamics continue to shape clinical adoption, regulatory strategy, and commercialization priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct enabling conditions and barriers. In the Americas, well-established clinical trial networks and advanced reimbursement frameworks create an environment conducive to the adoption of novel sustained-release and implantable solutions; however, payers' emphasis on cost-effectiveness necessitates robust health economics evidence and real-world outcome demonstration to support broad uptake.

In Europe, Middle East & Africa, fragmented regulatory frameworks and heterogeneous payer environments require adaptive market-entry strategies that consider country-level intelligence, while centralized pathways and harmonized clinical requirements in some jurisdictions may facilitate multi-country rollouts. Asia-Pacific presents a diverse landscape where high-volume markets, local manufacturing capacity, and growing clinical research ecosystems coexist with variable regulatory maturity; these conditions favor scalable and cost-efficient delivery solutions, and partnerships with regional manufacturers and clinical sites often accelerate entry and adoption. Across regions, local supply-chain resilience, regulatory timelines, and provider training needs determine the pace and scale of commercialization.

Integrated capabilities across device design, formulation science, regulatory expertise, and manufacturing scalability are reshaping competitive advantage in ophthalmic delivery

Competitive positioning in ophthalmic drug delivery is increasingly determined by integrated capabilities that span device engineering, formulation expertise, clinical development, and regulatory execution. Companies that combine deep expertise in controlled-release technologies with proven sterile manufacturing capacity and clear regulatory pathways maintain an advantage in bringing differentiated therapies to market. Strategic collaborations between pharmaceutical sponsors and device-focused partners are also prevalent, enabling co-development models that align technical innovation with clinical endpoints and payer evidence requirements.

Intellectual property portfolios centered on delivery-device interfaces, sustained-release matrices, and biocompatible materials are proving to be critical differentiators. At the same time, firms that invest in scaled manufacturing and quality systems capable of supporting combination products demonstrate reduced time-to-market risk. Service providers, contract development and manufacturing organizations, and specialized component suppliers that offer validated processes and compliance support are gaining traction as strategic allies. Accordingly, success increasingly depends on orchestrating cross-functional partnerships that deliver end-to-end solutions from concept through commercialization.

Adopt integrated regulatory, supply-chain, and evidence-generation strategies while fostering alliances and IP protection to accelerate adoption and reduce commercialization risk

Industry leaders should pursue a set of actionable initiatives designed to accelerate development, enhance adoption, and strengthen commercial positioning in ophthalmic drug delivery. First, embed regulatory and health economics planning at early stages of product design to create evidence dossiers that align with payer expectations and facilitate reimbursement negotiations. Second, prioritize modular supply-chain strategies that combine near-shore manufacturing with validated multi-sourcing to reduce exposure to tariff volatility and material shortages. Third, invest in combination-product development by forming alliances that marry proprietary molecules with differentiated delivery platforms, thereby creating higher barriers to entry and more compelling value propositions for clinicians and patients.

Moreover, expand evidence-generation programs to include real-world outcomes and patient-reported measures that demonstrate reduced treatment burden and improved adherence. Simultaneously, design commercialization pilots with provider training and digital-support tools to accelerate clinician acceptance and ensure correct utilization. Finally, maintain a disciplined IP strategy focused on both core delivery mechanisms and user-interface elements to protect commercial differentiation while enabling selective licensing or co-development arrangements where strategic.

A transparent, triangulated research methodology combining expert interviews, literature synthesis, and scenario analysis underpins the insights and recommendations presented

The research approach underpinning this analysis combined multi-source intelligence, expert interviews, and document synthesis to build a comprehensive view of the ophthalmic drug delivery landscape. Primary qualitative input was obtained through structured interviews with clinical investigators, regulatory advisors, procurement leaders, and product development executives to capture practical insights on clinical workflows, device handling, and payer evidence needs. Secondary sources included peer-reviewed literature, regulatory guidance documents, and technical whitepapers to corroborate mechanistic understanding of delivery technologies and formulation performance.

Analytical methods emphasized triangulation across sources to validate themes and identify actionable implications. Supply-chain and regulatory impacts were assessed through scenario mapping to reflect the operational consequences of tariff changes and policy adjustments. Competitive dynamics were evaluated by examining public disclosures, patent filings, and clinical trial registries to understand capability clusters and partnership trends. The methodological framework prioritized transparency and reproducibility in how insights were derived, ensuring that recommendations are grounded in verifiable evidence and expert judgment.

Strategic convergence of technology, evidence generation, and supply-chain resilience will determine which organizations convert ophthalmic delivery innovation into enduring clinical and commercial success

In conclusion, the ophthalmic drug delivery arena is at an inflection point where technological advances, regulatory expectations, and supply-chain realities intersect to redefine how therapies are developed and commercialized. Sustained-release platforms, innovative device modalities, and improved formulation strategies are converging to reduce treatment burden and expand therapeutic options for complex ocular conditions. Simultaneously, economic and policy pressures are driving organizations to adopt resilient sourcing strategies and to generate the kind of clinical and economic evidence that payers and providers require for adoption.

Looking ahead, organizations that integrate cross-functional capabilities-combining device engineering, formulation science, regulatory planning, and real-world evidence generation-will be best positioned to translate innovation into clinical impact. By focusing on partnerships that accelerate scalability, protecting critical intellectual property, and aligning evidence plans with payer expectations, companies can de-risk development while delivering meaningful benefits to patients and healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rise of biodegradable intravitreal implants offering sustained drug release for wet AMD patients
  • 5.2. Integration of microneedle-based ocular patches for minimally invasive therapy delivery in chronic eye conditions
  • 5.3. Adoption of novel nanocarrier formulations for enhanced corneal penetration and bioavailability
  • 5.4. Expansion of gene therapy approaches using viral vectors for inherited retinal disease treatment
  • 5.5. Growth of patient-friendly in situ gelling eye drops enabling prolonged drug retention on ocular surface
  • 5.6. Use of contact lenses embedded with drug reservoirs for controlled glaucoma medication release
  • 5.7. Partnerships between biotech firms and ophthalmic device manufacturers to co-develop combination drug-device products
  • 5.8. Implementation of artificial intelligence predictive models to optimize personalized dosing in ophthalmic drug administration
  • 5.9. Emergence of 3D printed ocular implants tailored to individual patient anatomy for targeted drug delivery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Ophthalmic Drug Delivery System Market, by Drug Type

  • 8.1. Anti-Allergy
  • 8.2. Anti-Glaucoma
  • 8.3. Anti-Infective
  • 8.4. Anti-Inflammatory
  • 8.5. Anti-VEGF

9. Ophthalmic Drug Delivery System Market, by Delivery Device Type

  • 9.1. Contact Lens Drug Delivery
  • 9.2. Intraocular Implants
  • 9.3. Microneedles
  • 9.4. Ocular Inserts
  • 9.5. Ophthalmic Sprays
  • 9.6. Topical Gels

10. Ophthalmic Drug Delivery System Market, by Product Type

  • 10.1. Over-The-Counter Drug Formulations
  • 10.2. Prescription Drug Formulations
    • 10.2.1. Controlled-Release Formulations
    • 10.2.2. Standard Formulations

11. Ophthalmic Drug Delivery System Market, by Formulation Type

  • 11.1. Liquid Formulations
  • 11.2. Semi-Solid Formulations
    • 11.2.1. Creams
    • 11.2.2. Gels
    • 11.2.3. Ointments
  • 11.3. Solid Formulations
    • 11.3.1. Capsules
    • 11.3.2. Tablets

12. Ophthalmic Drug Delivery System Market, by Mode Of Delivery

  • 12.1. Intraocular
  • 12.2. Intravitreal
  • 12.3. Periocular
  • 12.4. Systemic
  • 12.5. Topical

13. Ophthalmic Drug Delivery System Market, by Application

  • 13.1. Allergy Treatment
  • 13.2. Dry Eye Syndrome
  • 13.3. Glaucoma
  • 13.4. Ocular Infections
  • 13.5. Retinal Disorders
  • 13.6. Surgical Recovery

14. Ophthalmic Drug Delivery System Market, by End User

  • 14.1. Hospitals
  • 14.2. Ophthalmic Clinics
  • 14.3. Research Organizations

15. Ophthalmic Drug Delivery System Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Ophthalmic Drug Delivery System Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Ophthalmic Drug Delivery System Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. AbbVie Inc.
    • 18.3.3. Alcon Vision LLC
    • 18.3.4. Apotex Inc.
    • 18.3.5. AptarGroup, Inc.
    • 18.3.6. Bausch Health Companies Inc.
    • 18.3.7. Bayer AG
    • 18.3.8. Carl Zeiss AG
    • 18.3.9. DifGen Pharmaceuticals LLC
    • 18.3.10. EyePoint Pharmaceuticals, Inc.
    • 18.3.11. F. Hoffmann-La Roche AG
    • 18.3.12. Genentech, Inc.
    • 18.3.13. Gerresheimer AG
    • 18.3.14. Iskon Remedies
    • 18.3.15. Johnson & Johnson Service, Inc.
    • 18.3.16. Mati Therapeutics, Inc.
    • 18.3.17. Merck KGaA
    • 18.3.18. MgShell S.R.L.
    • 18.3.19. Nicox SA
    • 18.3.20. Novartis AG
    • 18.3.21. Ocular Therapeutix Inc.
    • 18.3.22. Oculis SA
    • 18.3.23. Pfizer Inc.
    • 18.3.24. Recipharm AB
    • 18.3.25. Regeneron Pharmaceuticals, Inc.
    • 18.3.26. Santen Pharmaceutical Co., Ltd.
    • 18.3.27. Sun Pharmaceutical Industries, Inc.
    • 18.3.28. Terumo Corporation
    • 18.3.29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-ALLERGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-ALLERGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-ALLERGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-ALLERGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-ALLERGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-ALLERGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-GLAUCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-GLAUCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-GLAUCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-GLAUCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-GLAUCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFECTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFECTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFECTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFECTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFECTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFLAMMATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFLAMMATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFLAMMATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-INFLAMMATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-VEGF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-VEGF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-VEGF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ANTI-VEGF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTACT LENS DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTACT LENS DRUG DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTACT LENS DRUG DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTACT LENS DRUG DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTACT LENS DRUG DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTACT LENS DRUG DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MICRONEEDLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INSERTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INSERTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INSERTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INSERTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INSERTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INSERTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OVER-THE-COUNTER DRUG FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OVER-THE-COUNTER DRUG FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OVER-THE-COUNTER DRUG FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OVER-THE-COUNTER DRUG FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OVER-THE-COUNTER DRUG FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OVER-THE-COUNTER DRUG FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTROLLED-RELEASE FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTROLLED-RELEASE FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTROLLED-RELEASE FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTROLLED-RELEASE FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTROLLED-RELEASE FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CONTROLLED-RELEASE FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STANDARD FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STANDARD FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STANDARD FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STANDARD FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STANDARD FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY STANDARD FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY LIQUID FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY LIQUID FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAOCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVITREAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVITREAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVITREAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVITREAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY INTRAVITREAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PERIOCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PERIOCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PERIOCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PERIOCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PERIOCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PERIOCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SYSTEMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SYSTEMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SYSTEMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SYSTEMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ALLERGY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ALLERGY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ALLERGY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ALLERGY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY ALLERGY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY EYE SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY EYE SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY EYE SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRY EYE SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GLAUCOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GLAUCOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GLAUCOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GLAUCOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY GLAUCOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OCULAR INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RETINAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RETINAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RETINAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RETINAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RETINAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RETINAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SURGICAL RECOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SURGICAL RECOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SURGICAL RECOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SURGICAL RECOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SURGICAL RECOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SURGICAL RECOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SOLID FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY MODE OF DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY DELIVERY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY PRESCRIPTION DRUG FORMULATIONS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY FORMULATION TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA OPHTHALMIC DRUG DELIVERY SYSTEM MARKET SIZE, BY SEMI-SOLID FORMULATIONS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA OPHTHALMIC DRUG